Massachusetts-based medical device company Infraredx has refinanced its debt with GE Capital. GE Capital upped the coronary artery imaging company’s credit from $6.6 million to $20 million, according to a press release. The company is gearing up for a commercial launch in Japan and will use much of the funding earmarked for commercialization as working […]
Its $3.6 billion deal to buy King Pharmaceuticals will be Pfizer's largest since it bought rival Wyeth for $68 billion in 2009. That acquisition included Wyeth's vaccine plant in Sanford, North Carolina, where Pfizer plans to cut 400 workers over the next five years, according to the News & Observer.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Food and Drug Administration gave InfraReDx Inc. 510(k) clearance for the company's LipiScan IVUS coronary imaging system. The device employs both so-called "near-infrared" spectroscopy and intravascular ultrasound technology to give cardiologists a grayscale IVUS image of a coronary artery, along with a map of lipid core coronary plaques within a blood vessel.